Chong Kun Dang exports biosimilar referencing anemia treatment to Japanese branch
Chong Kun Dang(CEO Young-Joo Kim) recently signed a business partnership agreement of ‘CKD-11101,’ a second-generation anemia treatment biosimilar, with a U.S. global pharmaceutical company’s Japanese branch. The agreement includes exportation of its finished drugs as well.
Under the agreement, ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.